about
Common genetic variation and the control of HIV-1 in humansStimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infectionGenetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association studyFailure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infectionsCost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failurePhylogenetic approach reveals that virus genotype largely determines HIV set-point viral loadAssessing predicted HIV-1 replicative capacity in a clinical settingDeterminants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapyLong-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimensAdherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort StudyThe individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patientsPersistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgroundsSimultaneously estimating evolutionary history and repeated traits phylogenetic signal: applications to viral and host phenotypic evolutionUsing an epidemiological model for phylogenetic inference reveals density dependence in HIV transmissionCorrection: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing RegimensChallenges and opportunities in estimating viral genetic diversity from next-generation sequencing dataMinor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patientsEarly antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruptionProfound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infectionComplement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection[Antiretroviral therapy].In Vivo and in Vitro Proteome Analysis of Human Immunodeficiency Virus (HIV)-1-infected, Human CD4+ T Cells.Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection.Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts.Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals.Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individualsMutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.Host and viral genetic correlates of clinical definitions of HIV-1 disease progression.Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.Parent-offspring regression to estimate the heritability of an HIV-1 trait in a realistic setup.Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe.Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.Antiretroviral resistance during successful therapy of HIV type 1 infection.Estimating the basic reproductive number from viral sequence data.Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission.Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations.Update of the drug resistance mutations in HIV-1: December 2009.
P50
Q21092450-584AE7C3-AFE0-499F-B805-78BB10766F73Q24536249-5F9EC83C-A2D5-4021-B64A-0AA1421B36E2Q28269827-90B8669A-8391-4AB9-884A-F6E7A9B528A7Q28295313-F0C95762-95F7-4D21-AE89-F89EE009CD2BQ28469116-B7D7585A-C64C-482C-8B46-9419649AEE56Q28475652-616254B6-FE4A-4642-8A3D-C5CE341A8E9CQ28477801-37926B08-097B-40BD-B13D-2B81E0FB2C7CQ28478666-8A05231D-90BC-4CB2-A6DD-16F675A83BF7Q28485321-DF81B13C-06E1-4CA6-B6B1-2E0C58B9C7DCQ28534423-CF9772CA-36EB-4738-92E6-B902C3AE48F6Q28536153-62204FD9-180F-4435-A34A-C8F083C58C96Q28544845-ABA18344-8B0E-4DC5-8FEA-48F690031430Q28652426-388936E5-5E7C-4DA2-B872-90816B17AEA1Q28660879-8BC30F7E-FEE6-4A08-A8EB-77C731438F06Q28683189-317120A3-73DE-47F1-9A74-C8913AC7FAFDQ28727944-B6913C24-333D-4A4E-85AF-F1149B6528C1Q28728304-14102891-7FC5-4A5E-912E-71B5006C10DDQ28742727-E4096D0E-666D-4FCC-895F-6F14D110A965Q28748901-8D0FA6D6-D56E-41D7-A52D-EE3822E4B193Q28766705-F9D80A0F-FC43-4622-AFD0-40B2564D402AQ30365431-CD271EAB-76F3-4B23-9E68-F7CE32C73D91Q30398955-49B6E87E-3635-49A6-8788-326317AF89CCQ30469621-E29264BA-12CD-402E-AACA-A7C26FE00543Q33269667-74650855-E9A3-4773-9AF7-B6537EC7CBBAQ33280133-FB0E4926-2A24-4347-B21B-0142E8189A12Q33410342-98C1F69E-29D1-4990-BA8E-3E27A9A6C1B9Q33535874-D953CF95-880D-458A-913B-5718961C75CAQ33603586-84E3763C-8661-4D1B-984F-4BDCF655D86CQ33605758-B70E700D-829F-4E21-B94A-888CC87A7567Q33638320-AC5BFF8D-1EAA-4E68-A4D8-51A1809C557BQ33716348-92061A84-DE6D-4D1A-B6B1-49D16F44D893Q33722738-C37A7232-1625-484D-8C19-2D0EBF4C13A6Q33788085-122B700F-0EB5-42DB-BC83-8CB6FAE7CB3DQ33843345-1AA43F33-94FB-4C0E-AD96-53959E535164Q33883813-3C5CA233-E880-45E1-8D82-254862FE6004Q33919308-EB9C9C42-49EE-409C-AC58-FAB0D92DE2BFQ34010717-010F68D8-41D6-490F-89F4-6B770C2EA3E6Q34029430-C8FEEA9B-295C-4921-869A-AB67C6432F84Q34044256-7DA715CE-F81F-433E-A419-148F1D17DDB3Q34092408-2C7AFADE-3715-466D-BE85-634A62D56680
P50
description
Virologe
@de
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Huldrych F Günthard
@ast
Huldrych F Günthard
@en
Huldrych F Günthard
@es
Huldrych F Günthard
@sl
Huldrych F. Günthard
@de
type
label
Huldrych F Günthard
@ast
Huldrych F Günthard
@en
Huldrych F Günthard
@es
Huldrych F Günthard
@sl
Huldrych F. Günthard
@de
altLabel
Huldrych Fritz Günthard
@en
Huldrych Günthard
@en
prefLabel
Huldrych F Günthard
@ast
Huldrych F Günthard
@en
Huldrych F Günthard
@es
Huldrych F Günthard
@sl
Huldrych F. Günthard
@de
P227
P1053
F-1724-2011
P106
P21
P227
P2798
P31
P3829
P496
0000-0002-1142-6723
P569
1961-01-01T00:00:00Z